世界の遺伝子デリバリー技術市場2021-2028:モード別(AAV、レンチウイルス、レトロウイルス)、用途別(遺伝子治療、細胞治療)、方法別(ex-vivo、in-vivo)、地域別

◆英語タイトル:Gene Delivery Technologies Market Size, Share & Trends Analysis Report By Mode (AAV, Lentivirus, Retrovirus), By Application (Gene Therapy, Cell Therapy), By Method (Ex-vivo, In-vivo), By Region, And Segment Forecasts, 2021 - 2028
◆商品コード:GV21MC025
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2021年2月26日
◆ページ数:150
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥678,300見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥792,300見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,020,300見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

グランドビューリサーチ社は、世界の遺伝子デリバリー技術市場規模が2028年までに79億ドルに達すると予測しています。2021年から2028年までに年平均15.1%成長する見通しです。本調査レポートでは、遺伝子デリバリー技術の世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、産業動向、競争状況、モード別(生物学的、化学的、物理的)分析、用途別(遺伝子治療、細胞治療、ワクチン、研究)分析、方法別(ex-vivo、in-vivo、inーvitro)分析、地域別分析、企業情報などを掲載しています。
・調査手法・範囲
・エグゼクティブサマリー
・産業動向
・競争状況
・遺伝子デリバリー技術の世界市場規模:モード別(生物学的、化学的、物理的)
・遺伝子デリバリー技術の世界市場規模:用途別(遺伝子治療、細胞治療、ワクチン、研究)
・遺伝子デリバリー技術の世界市場規模:方法別(ex-vivo、in-vivo、inーvitro)
・遺伝子デリバリー技術の世界市場規模:地域別
・企業情報
【レポートの概要】

Gene Delivery Technologies Market Growth & Trends

The global gene delivery technologies market size is expected to reach USD 7.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.1% from 2021 to 2028. Technological advancements in viral vectors, a growing pipeline of advanced therapies, and a rising number of regulatory approvals for advance therapy products are some key driving forces of the market.

Several novel tools are being introduced for genetic alterations that have facilitated the scientific community to delineate the disease intricacies at the genomic level, leading to the emergence of novel gene delivery approaches. Furthermore, ongoing research to develop clinically relevant vectors including viral and non-viral vectors to combat chronic illnesses such as cancer, Alzheimer’s, and others through advanced therapies is spurring the market revenue.

An increase in investment and financing in the space to support the research, development, and manufacturing of various modes of gene transfer further accelerates the revenue growth. Currently, around 70% of gene and cell therapy programs are based on viral vectors leading to organic revenue growth for biological delivery technologies. The operating players are investing significantly to scale up their viral vector manufacturing capability and meet the growing demand.

Considering growing opportunities in physio-chemical gene delivery approaches, key players are making focused efforts to boost their business presence. For instance, nanoparticles have proven their efficiency as promising vehicles for clinical usage owing to their tunable morphology, and biological behaviors. Such ongoing developments in the space are anticipated to accelerate revenue growth in this market in the coming years.

Gene Delivery Technologies Market Report Highlights

• The wide implementation of biological gene delivery technologies in clinical usage owing to their high efficiency and specificity has resulted in the segment’s largest revenue share in 2020

• Gene therapy development is the key revenue-generating application in the 2020 market owing to constantly expanding pipeline programs of therapies against life-threatening conditions coupled with the recent success of CAR-T therapies

• The recent pandemic of SARS-CoV-2 has also resulted in substantial global investments in R&D of viral vector-based vaccine to combat the virus, resulting in lucrative growth of this segment

• The ex vivo method accounted for the major revenue share owing to its advantages such as high transduction efficiency and less immunogenic responses

• However, both in vivo and ex vivo have shown clinical success in the treatment of chronic conditions, thus both segments are expected to witness lucrative growth in the coming years

• Given the high number of biotech companies and a favorable regulatory environment in the U.S.; North America dominated the global market in terms of revenue

• On the other hand, Asia Pacific is projected to grow at the fastest pace during the forecast period

• Constantly evolving CDMO and viral vector manufacturing landscapes through plant expansions and new sites being built across the Asian countries is spurring the adoption of vectors in this region

• The key players are engaged in collaboration with therapy developers to support their product development process

【レポートの目次】

Table of Contents

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and Forecast Timeline
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume Price Analysis (Model 2)
1.6.2.1 Approach 2: Volume Price Analysis
1.6.2.2 Revenue Modeling
1.7 List of Secondary Sources
1.8 List of Primary Sources
Chapter 2 Executive Summary
2.1 Gene Delivery Technologies Market Outlook
2.1.1 Market Summary
2.2 Gene Delivery Technologies Market: Market Segmentation
2.3 Gene Delivery Technologies Market: Competitive Insights
Chapter 3 Gene Delivery Technologies Market: Industry Outlook
3.1 Parent Market
3.2 Ancillary Market
3.3 Penetration & Growth Prospect Mapping for Applications, 2020
3.4 Market Dynamics
3.4.1 Market driver analysis
3.4.1.1 Advances in gene and cell research and therapeutic delivery
3.4.1.2 Increase in funding by government and private players
3.4.1.3 Rising competition amongst market players
3.4.2 Market restraint analysis
3.4.2.1 High Cost of Gene Delivery Systems
3.4.2.2 Home brew reagents restricts sale of commercial products
3.4.3 Market opportunity analysis
3.4.3.1 Rising pressure on drug developers to meet consumer’s therapeutics demand
3.4.3.2 Expanding market in regions such as APAC and LATAM
3.4.4 Market Challenge analysis
3.4.4.1 Technical challenges related to gene delivery techniques
3.5 Gene Delivery Technologies Market – Porter’s Analysis
3.5.1 Competitive Rivalry
3.5.2 Threat of New Entrants
3.5.3 Threat of Substitutes
3.5.4 Bargaining Power of Suppliers
3.5.5 Bargaining Power of Buyers
3.6 Gene Delivery Technologies Market – SWOT Analysis
3.6.1 Political and Legal
3.6.1.1 Strengths
3.6.1.2 Weaknesses
3.6.1.3 Opportunities
3.6.1.4 Threats
3.6.2 Economic
3.6.2.1 Strengths
3.6.2.2 Weaknesses
3.6.2.3 Opportunities
3.6.2.4 Threats
3.6.3 Technological
3.6.3.1 Strengths
3.6.3.2 Weaknesses
3.6.3.3 Opportunities
3.6.3.4 Threats
3.7 Regulatory Framework
3.8 COVID-19 Impact Analysis
3.8.1 Challenge Analysis
3.8.2 Opportunity Analysis
3.8.3 Key developments & activities
3.9 Strategic Alliance Analysis: Gene Delivery Technologies Market
3.9.1 Mergers & Acquisitions:
3.9.2 Technological Collaborations:
3.9.3 Licensing and partnership:
3.9.4 New product development:
Chapter 4 Gene Delivery Technologies Market: Competitive Landscape
4.1 Strategy Framework
4.2 Market Participation Categorization
4.3 Competitive Dashboard Analysis
4.4 List of Potential end users
4.5 Market Differentiators
4.6 Recent Developments & Impact Analysis, By Key Market Participants
4.6.1 Impact Analysis
4.6.2 Regional Network Map
4.7 Private companies
4.7.1 List of emerging players
Chapter 5 Gene Delivery Technologies Market: Mode Business Analysis
5.1 Gene Delivery Technologies Market: Mode Movement Analysis
5.2 Biological
5.2.1 Global biological gene delivery technologies market, 2017 – 2028 (USD Million)
5.2.2 AAV
5.2.2.1 Global adenovirus gene delivery technologies market, 2017 – 2028 (USD Million)
5.2.3 Adenovirus
5.2.3.1 Global adenovirus gene delivery technologies market, 2017 – 2028 (USD Million)
5.2.4 Retrovirus
5.2.4.1 Global retrovirus gene delivery technologies market, 2017 – 2028 (USD Million)
5.2.5 Lentivirus
5.2.5.1 Global lentivirus gene delivery technologies market, 2017 – 2028 (USD Million)
5.2.6 Other Virus
5.2.6.1 Global other virus gene delivery technologies market, 2017 – 2028 (USD Million)
5.2.7 Non – viral
5.2.7.1 Global non – viral gene delivery technologies market, 2017 – 2028 (USD Million)
5.3 Chemical
5.3.1 Global chemical gene delivery technologies market, 2017 – 2028 (USD Million)
5.4 Physical
5.4.1 Global physical gene delivery technologies market, 2017 – 2028 (USD Million)
Chapter 6 Gene Delivery Technologies Market: Application Business Analysis
6.1 Market: Application Movement Analysis
6.2 Gene Therapy
6.2.1 Market for gene therapy development, 2017 – 2028 (USD Million)
6.3 Cell Therapy
6.3.1 Market for cell therapy development, 2017 – 2028 (USD Million)
6.4 Vaccines
6.4.1 Market for vaccine development, 2017 – 2028 (USD Million)
6.5 Research
6.5.1 Market for research, 2017 – 2028 (USD Million)
Chapter 7 Gene Delivery Technologies Market: Method Business Analysis
7.1 Gene Delivery Technologies Market: Method Movement Analysis
7.2 Ex Vivo
7.2.1 Global ex vivo gene delivery technologies market, 2017 – 2028 (USD Million)
7.3 In Vivo
7.3.1 Global in vivo gene delivery technologies market, 2017 – 2028 (USD Million)
7.4 In Vitro
7.4.1 Global in vitro gene delivery technologies market, 2017 – 2028 (USD Million)
Chapter 8 Regional Business Analysis
8.1 Market: Regional Movement Analysis, 2020 & 2028
8.2 North America
8.2.1 Market estimates and forecast, 2017 – 2028 (USD Million)
8.2.2 U.S.
8.2.2.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.2.2.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.2.2.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.2.3 Canada
8.2.3.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.2.3.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.2.3.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.3 Europe
8.3.1 Market estimates and forecast, 2017 – 2028 (USD Million)
8.3.2 Germany
8.3.2.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.3.2.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.3.2.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.3.3 U.K.
8.3.3.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.3.3.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.3.3.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.3.4 France
8.3.4.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.3.4.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.3.4.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.3.5 Italy
8.3.5.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.3.5.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.3.5.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.3.6 Spain
8.3.6.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.3.6.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.3.6.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.4 Asia Pacific
8.4.1 Market estimates and forecast, 2017 – 2028 (USD Million)
8.4.2 China
8.4.2.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.4.2.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.4.2.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.4.3 India
8.4.3.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.4.3.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.4.3.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.4.4 South Korea
8.4.4.1 SMarket estimates and forecast, 2017 – 2028 by mode (USD Million)
8.4.4.2 SMarket estimates and forecast, 2017 – 2028 by application (USD Million)
8.4.4.3 SMarket estimates and forecast, 2017 – 2028 by method (USD Million)
8.4.5 Australia
8.4.5.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.4.5.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.4.5.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.4.6 Japan
8.4.6.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.4.6.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.4.6.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.5 Latin America
8.5.1 Market estimates and forecast, 2017 – 2028 (USD Million)
8.5.2 Brazil
8.5.2.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.5.2.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.5.2.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.5.3 Mexico
8.5.3.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.5.3.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.5.3.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.6 Middle East & Africa (MEA)
8.6.1 Market estimates and forecast, 2017 – 2028 (USD Million)
8.6.2 South Africa
8.6.2.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.6.2.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.6.2.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
8.6.3 Saudi Arabia
8.6.3.1 Market estimates and forecast, 2017 – 2028 by mode (USD Million)
8.6.3.2 Market estimates and forecast, 2017 – 2028 by application (USD Million)
8.6.3.3 Market estimates and forecast, 2017 – 2028 by method (USD Million)
Chapter 9 Company Profiling
9.1 Company Profiles
9.1.1 F. Hoffmann – La Roche AG
9.1.1.1 Company overview
9.1.1.2 Financial performance
9.1.1.3 Product benchmarking
9.1.1.4 Strategic initiatives
9.1.2 Thermo Fisher Scientific, Inc.
9.1.2.1 Company overview
9.1.2.2 Financial performance
9.1.2.3 Product benchmarking
9.1.2.4 Strategic initiatives
9.1.3 QIAGEN
9.1.3.1 Company overview
9.1.3.2 Financial performance
9.1.3.3 Product benchmarking
9.1.3.4 Strategic initiatives
9.1.4 Horizon Discovery Group Co.
9.1.4.1 Company overview
9.1.4.2 Financial performance (Sekisui Chemical Co., Ltd.)
9.1.4.3 Product benchmarking
9.1.4.4 Strategic initiatives
9.1.5 OriGene Technologies, Inc.
9.1.5.1 Company overview
9.1.5.2 Product benchmarking
9.1.5.3 Strategic initiatives
9.1.6 Oxford Biomedica
9.1.6.1 Company overview
9.1.6.2 Product benchmarking
9.1.6.3 Strategic initiatives
9.1.7 SignaGen Laboratories
9.1.7.1 Company overview
9.1.7.2 Financial performance
9.1.7.3 Product benchmarking
9.1.7.4 Strategic initiatives
8.1.8 Vectalys
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic Initiatives
9.1.9 Takara Bio Inc.
9.1.9.1 Company overview
9.1.9.2 Financial performance
9.1.9.3 Product benchmarking
9.1.9.4 Strategic Initiatives
9.1.10 Bio – Rad Laboratories, Inc.
9.1.10.1 Company overview
9.1.10.2 Financial performance
9.1.10.3 Product benchmarking
9.1.10.1 Strategic Initiatives
9.1.11 System Biosciences llc
9.1.11.1 Company overview
9.1.11.2 Financial performance
9.1.11.3 Product benchmarking
9.1.11.4 Strategic Initiatives
9.1.12 Catalent Inc.
9.1.12.1 Company overview
9.1.12.2 Financial performance
9.1.12.3 Product benchmarking
9.1.12.4 Strategic initiatives
9.1.13 Promega Corporation
9.1.13.1 Company overview
9.1.13.2 Financial performance
9.1.13.3 Product benchmarking
9.1.13.4 Strategic initiatives
9.1.14 Agilent Technologies
9.1.14.1 Company overview
9.1.14.2 Financial performance
9.1.14.3 Product benchmarking
9.1.14.4 Strategic initiatives
9.1.15 Sirion – Biotech GmbH
9.1.15.1 Company overview
9.1.15.2 Financial performance
9.1.15.3 Product benchmarking
9.1.15.4 Strategic initiatives

List of Tables

Table 1 List of secondary sources
Table 2 Common problems related to cell transfection
Table 3 North America gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 4 North America biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 5 North America gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 6 North America gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 7 U.S. gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 8 U.S. biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 9 U.S. gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 10 U.S. gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 11 Canada gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 12 Canada biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 13 Canada gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 14 Canada gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 15 Europe gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 16 Europe biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 17 Europe gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 18 Europe gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 19 Germany gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 20 Germany biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 21 Germany gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 22 Germany gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 23 U.K. gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 24 U.K. biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 25 U.K. gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 26 U.K. gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 27 France gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 28 France biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 29 France gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 30 France gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 31 Italy gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 32 Italy biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 33 Italy gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 34 Italy gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 35 Spain gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 36 Spain biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 37 Spain gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 38 Spain gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 39 Asia Pacific gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 40 Asia Pacific biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 41 Asia Pacific gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 42 Asia Pacific gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 43 China gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 44 China biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 45 China gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 46 China gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 47 India gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 48 India biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 49 India gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 50 India gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 51 South Korea gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 52 South Korea biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 53 South Korea gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 54 South Korea gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 55 Australia gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 56 Australia biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 57 Australia gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 58 Australia gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 59 Japan gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 60 Japan biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 61 Japan gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 62 Japan gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 63 Latin America gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 64 Latin America biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 65 Latin America gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 66 Latin America gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 67 Brazil gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 68 Brazil biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 69 Brazil gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 70 Brazil gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 71 Mexico gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 72 Mexico biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 73 Mexico gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 74 Mexico gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 75 MEA gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 76 MEA biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 77 MEA gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 78 MEA gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 79 South Africa gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 80 South Africa biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 81 South Africa gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 82 South Africa gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)
Table 83 Saudi Arabia gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 84 Saudi Arabia biological gene delivery technologies market estimates & forecasts, by mode, 2017 - 2028 (USD Million)
Table 85 Saudi Arabia gene delivery technologies market estimates & forecasts, by application, 2017 - 2028 (USD Million)
Table 86 Saudi Arabia gene delivery technologies market estimates & forecasts, by method, 2017 - 2028 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market revenue modeling
Fig. 9 Market revenue modeling: Considerations
Fig. 10 Market snapshot, 2020 (USD Million)
Fig. 11 gene delivery technologies market segmentation
Fig. 12 Penetration & growth prospect mapping for products, 2020
Fig. 13 Market driver relevance analysis (Current & future impact)
Fig. 14 Vectors used in Gene Therapy Trials as of 2019
Fig. 15 Gene therapy clinical trials number as of 2019
Fig. 16 Number of lentiviral vector clinical trials initiated by year and phase
Fig. 17 Market restrain relevance analysis (Current & future impact)
Fig. 18 Strategy framework
Fig. 19 Market participation categorization
Fig. 20 Gene delivery technologies market: Mode outlook and key takeaways
Fig. 21 Gene delivery technologies market: Mode movement analysis
Fig. 22 Global biological gene delivery technologies market, 2017 - 2028 (USD Million)
Fig. 23 Global adenovirus gene delivery technologies market, 2017 - 2028 (USD Million)
Fig. 24 Global retrovirus gene delivery technologies market, 2017 - 2028 (USD Million)
Fig. 25 Global AAV gene delivery technologies market, 2017 - 2028 (USD Million)
Fig. 26 Global lentivirus gene delivery technologies market, 2017 - 2028 (USD Million)
Fig. 27 Global other virus gene delivery technologies market, 2017 - 2028 (USD Million)
Fig. 28 Global non-viral DNA gene delivery technologies market, 2017 - 2028 (USD Million)
Fig. 29 Global chemical gene delivery technologies market, 2017 - 2028 (USD Million)
Fig. 30 Global physical gene delivery technologies market, 2017 - 2028 (USD Million)
Fig. 31 Gene delivery technologies market: Application outlook and key takeaways
Fig. 32 Gene delivery technologies market: Application movement analysis
Fig. 33 Global gene delivery technologies market for gene therapy development, 2017 - 2028 (USD Million)
Fig. 34 Global gene delivery technologies market for cell therapy development, 2017 - 2028 (USD Million)
Fig. 35 Global gene delivery technologies market for vaccine development, 2017 - 2028 (USD Million)
Fig. 36 Global gene delivery technologies market for research , 2017 - 2028 (USD Million)
Fig. 37 Gene delivery technologies market: Method outlook key takeaways
Fig. 38 Gene delivery technologies market: Method movement analysis
Fig. 39 Global ex vivo gene delivery technologies market, 2017 - 2028 (USD Million)
Fig. 40 Global in vivo gene delivery technologies market, 2017 - 2028 (USD Million)
Fig. 41 Global in vitro gene delivery technologies market, 2017 - 2028 (USD Million)
Fig. 42 Gene delivery technologies market: Regional outlook and key takeaways
Fig. 43 Gene delivery technologies market: Regional movement analysis
Fig. 44 North America gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 45 U.S.
Fig. 46 U.S. gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 47 Canada
Fig. 48 Canada gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 49 Europe
Fig. 50 Europe gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 51 Germany
Fig. 52 Germany gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 53 U.K.
Fig. 54 U.K. gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 55 France
Fig. 56 France gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 57 Italy
Fig. 58 Italy gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 59 Spain
Fig. 60 Spain gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 61 Asia Pacific
Fig. 62 Asia Pacific gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 63 China
Fig. 64 China gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 65 India
Fig. 66 India gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 67 South Korea
Fig. 68 South Korea gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 69 Australia
Fig. 70 Australia gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 71 Japan
Fig. 72 Japan gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 73 Latin America
Fig. 74 Latin America gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 75 Brazil
Fig. 76 Brazil gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 77 Mexico
Fig. 78 Mexico gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 79 MEA
Fig. 80 MEA gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 81 South Africa
Fig. 82 South Africa gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 83 Saudi Arabia
Fig. 84 Saudi Arabia gene delivery technologies market estimates and forecast, 2017 - 2028 (USD Million)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の遺伝子デリバリー技術市場2021-2028:モード別(AAV、レンチウイルス、レトロウイルス)、用途別(遺伝子治療、細胞治療)、方法別(ex-vivo、in-vivo)、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆